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Abstract
Objective:  This  study  aimed  to  identify  markers  of  metabolic  syndrome  (MS)  in  patients  with
phenylketonuria (PKU).
Methods: This  was  a  cross-sectional  study  consisting  of  58  PKU  patients  (ages  of  4-15  years):
29 patients  with  excess  weight,  and  29  with  normal  weight.  The  biochemical  variables  assessed
were  phenylalanine  (phe),  total  cholesterol,  HDL-c,  triglycerides,  glucose,  and  basal  insulin.
The  patients  had  Homeostasis  Model  Assessment  (HOMA)  and  waist  circumference  assessed.
Results:  No  inter-group  difference  was  found  for  phe.  Overweight  patients  had  higher  lev-
els of  triglycerides,  basal  insulin,  and  HOMA,  but  lower  concentrations  of  HDL-cholesterol,
when compared  to  the  eutrophic  patients.  Total  cholesterol/HDL-c  was  signiﬁcantly  higher  in
the  overweight  group.  A  positive  correlation  between  basal  insulin  level  and  HOMA  with  waist
circumference  was  found  only  in  the  overweight  group.
Conclusion:  The  results  of  this  study  suggest  that  patients  with  PKU  and  excess  weight  are
potentially vulnerable  to  the  development  of  metabolic  syndrome.  Therefore,  it  is  necessary
to  conduct  clinical  and  laboratory  monitoring,  aiming  to  prevent  metabolic  changes,  as  well  as
excessive  weight  gain  and  its  consequences,  particularly  cardiovascular  risk.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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PALAVRAS-CHAVE
Fenilcetonúria
Síndrome  metabólica;
Crianc¸as e
adolescentes;
Excesso  de  peso;
Dieta
Síndrome  metabólica  em  crianc¸as  e  adolescentes  com  fenilcetonúria
Resumo
Objetivo:  Determinar  marcadores  bioquímicos  da  síndrome  metabólica  em  pacientes  com  PKU.
Métodos:  Foram  avaliados  dois  grupos  de  pacientes  com  PKU,  4  a  15  anos  de  idade,  com
excesso de  peso  (29)  e  eutróﬁcos  (29).  As  variáveis  bioquímicas  avaliadas  foram  a  fenilala-
nina  (phe),  colesterol  total,  HDL-c,  triglicérides,  glicose  e  insulina  basal.  Foi  determinado  o
HOMA  e  mensurada  a  circunferência  da  cintura.
Resultados:  As  concentrac¸ões  de  phe,  de  colesterol  total  e  de  glicose  foram  equi-
valentes entre  os  grupos.  Os  pacientes  com  excesso  de  peso  apresentaram  maiores
concentrac¸ões de  triglicérides,  de  insulina  basal,  maiores  valores  da  determinac¸ão  do  HOMA,
menores  concentrac¸ões  de  HDL  colesterol  e  valores  mais  elevados  da  relac¸ão  do  colesterol
total/HDL-c.  Houve  correlac¸ão  positiva  entre  a  dosagem  de  insulina  basal  e  do  HOMA  com  a
circunferência  da  cintura  nos  pacientes  do  grupo  com  excesso  de  peso.
Conclusões: Os  resultados  deste  estudo  sugerem  que  pacientes  com  PKU  e  excesso  de  peso
são potencialmente  vulneráveis  ao  desenvolvimento  da  síndrome  metabólica.  Há,  portanto,
necessidade  de  acompanhamento  clínico-laboratorial  que  previna  as  alterac¸ões  metabólicas,  o
ganho  excessivo  de  peso  e  as  suas  consequências,  em  especial  o  risco  cardiovascular.
© 2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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Phenylketonuria  (PKU),  an  inborn  error  of  amino  acid
metabolism characterized  by  the  loss  or  reduction  in  the
activity of  hydroxylase  phenylalanine  (phe)  enzyme,  leads
to elevated  blood  levels  of  phe  and  its  metabolites,  result-
ing in  neurological  damage  that  culminates  in  irreversible
mental retardation.1,2 Disease  control  is  accomplished  by
prescribing a  diet  free  of  animal  protein  and  with  restricted
vegetable protein  consumption.  Due  to  the  diet  characteris-
tics, some  researchers  have  associated  PKU  to  a  tendency  of
excessive weight  gain  and  metabolic  syndrome  (MS).3--6 Con-
versely, excess  weight  and  metabolic  alterations  associated
with it  have  been  associated  to  increased  cardiovascular
risk, which  has  prompted  researchers  worldwide  to  consider
the importance  of  early  identiﬁcation  and  damage  preven-
tion in  at-risk  populations.7--11
Due  to  the  particularities  of  their  diet,  PKU  patients  can
be considered  a  vulnerable  group  to  metabolic  abnormali-
ties and  excess  weight.  Protein  restriction  favors  --  and  even
stimulates --  the  consumption  of  carbohydrate-rich  foods
(especially simple  carbohydrate)  and  lipids,  in  particular,
increasing the  risk  of  weight  gain.
MS  would  be  present  in  this  population  due  to  both  the
diet and  the  disease  itself.  The  detection  of  parameters
that identify  the  presence  of  MS  may  prevent  the  emer-
gence of  other  diseases  in  these  patients,  for  instance,
diabetes and  cardiovascular  disease.  The  International  Dia-
betes  Federation  (IDF)  considers  the  measurement  of  waist
circumference (WC),  associated  with  the  measurements  of
HDL cholesterol  (HDL-c),  triglycerides  (TG),  and  glucose  to
be parameters  for  the  identiﬁcation  of  MS.  The  latter  would
be deﬁned  by  WC  measurements  >  90th  percentile,  associ-
ated with  at  least  two  of  the  following  ﬁndings:  high  levels
of TG,  reduced  HDL-c,  and  increase  in  blood  pressure  and
fasting glucose.11
d
f
cThis  study  sought  to  determine  some  markers  of  MS  in
atients with  PKU  treated  at  the  Special  Genetics  Depart-
ent of  Hospital  das  Clinícas,  Universidade  Federal  de  Minas
erais  (SEG-HC-UFMG),  to  identify  risks  and  to  promote  bet-
er clinical  and  laboratory  control  of  the  disease  and  the
doption of  special  protocols  for  preventing  cardiovascular
amage.
ethods
 study  of  case  series  involving  58  children  and  adolescents
ith PKU,  aged  4  to  15  years  was  conducted.  Data  collection
as performed  between  October  of  2008  and  November  of
009. Patients  were  selected,  scheduled,  and  submitted  to
linical and  laboratory  assessment.
The  study  was  approved  by  the  Ethics  Committee  of
he Universidade  Federal  de  Minas  Gerais  (COEP-UFMG).  An
nformed  consent  was  signed  by  a  parent,  legal  guardian,
nd/or PKU  patient  older  than  6  years  old,  after  due  expla-
ations.
The groups  were  deﬁned  according  to  the  body
ass index  (BMI)  calculated  according  to  the  formula:
MI =  weight  (kg)/height2 (m).  The  value  obtained  was
ssessed using  the  growth  curves  of  the  World  Health
rganization (WHO)  for  children  aged  0-5  years  (2006)
nd 5-19  years  (2007),  considering  as  cutoffs  for  over-
eight and  obesity  BMI  >  85th  percentile  and  >  97th
ercentile, respectively.  The  groups  were  constituted  as  fol-
ows:  29  patients  with  normal  weight  and  29  with  excess
eight.
Measures of  waist  circumference  were  analyzed  in  accor-ance with  the  percentile  suggested  by  MacCarthy  et  al.
As  for  the  laboratory  tests,  patients  underwent  a  10-hour
ast, with  a  maximum  of  14  hours  of  fasting.  Serum  con-
entrations of  fasting  phe,  total  cholesterol  (TC),  HDL-c,
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riglycerides,  glucose,  and  basal  insulin  were  determined.
ipid and  glucose  levels  were  analyzed  enzymatically,
sing the  dry  chemical  technique.  Insulin  resistance  was
alculated using  the  mathematical  model  of  Matthews
t al.12 Lipid  measurements  were  conducted  in  accordance
ith the  I  Guideline  of  Atherosclerosis  in  Childhood  and
dolescence.13 The  mean  phe  (control  phe)  was  determined
y the  arithmetic  mean  of  the  last  12  measurements  and  was
onsidered inadequate  when  higher  than  the  maximum  ref-
rence value  for  the  age  range.14 Phe  levels  were  obtained
y ultramicroﬂuorometry,  using  the  ultramicro-ﬂuorometric
est (UMTEST  PKU).15
The  results  obtained  were  stored,  tabulated  in  an  elec-
ronic spreadsheet,  and  analyzed  using  SPSS,  release  15.0.
ample distribution  was  veriﬁed  by  the  Shapiro-Wilk’s  test.
tudent’s t-test  was  used  for  variables  with  normal  distri-
ution, whereas  the  nonparametric  Mann  Whitney  test  was
sed for  those  with  non-normal  distribution.  The  association
nalysis was  performed  using  Pearson’s  chi-squared  test  and
orrelation analysis  using  Spearman’s  test.
esults
able  1  describes  the  anthropometric  characteristics,  gen-
er distribution,  and  pubertal  stage  of  each  group.
The  groups  showed  similar  results  in  relation  to  blood
he control.  There  was  no  signiﬁcant  difference  (p  =  1)  in
ean phe  levels  of  the  individual:  50%  of  the  tests  were
dequate in  both  groups.  Regarding  the  phe  levels  collected
fter fasting  (p  =  0.14),  58.6%  of  tests  were  adequate  in
he excess  weight  group  and  41.4%  in  the  normal  weight
roup.
Patients from  the  excess  weight  group  had  higher
asal triglyceride  and  insulin  levels,  but  lower  HDL-
holesterol, when  compared  to  normal  weight  individuals
Table 2).The patients’  lipid  proﬁle,  when  analyzed  according
o pubertal  stage,  showed  higher  triglyceride  and  lower
DL-c levels  in  the  group  of  prepubertal  patients  with
xcess weight.  No  statistically  signiﬁcant  differences  were
t
t
e
v
Table  1  Characterization  of  two  groups  of  phenylketonuria  patie
Variables  
Excess  weight  (n  =  29)  
Age  (years)  9.3  (±  3.1)  
Weight  (kg)  35.8  (±  24.0)  
Height  (cm)  134.7  (±  20.2)  
Gender,  n  (%)
Female 18  (62.1)  
Male  11  (37.9)  
Pubertal stage,  n  (%)
Prepubertal 17 (58.6)
Pubertal  12  (42.8)  
a Student’s t-test (mean ± SD).
b Mann-Whitney’s test [median (± Q3-Q1)].
c Asymptotic Pearson’s chi squared test.Kanufre  VC  et  al.
bserved  between  the  two  groups  of  patients  at  pubertal
tage (Table  3).
The group  with  excess  weight  had  signiﬁcantly  higher  val-
es of  total  cholesterol/HDL-c  ratio,  blood  levels  of  basal
nsulin, and  HOMA  determination  (Table  4).
There  was  a  positive  correlation  between  basal  insulin
evel (p  =  0.00)  and  HOMA  (p  =  0.08)  with  WC,  but  only  in  the
roup with  excess  weight.
iscussion
xcess  weight  is  a current  public  health  problem  in  many
arts of  the  world.  In  Brazil,  despite  prevention  programs
ndertaken by  health  managers  and  professionals,  preva-
ence rates  have  increased  in  all  age  groups.16
The  concern  for  obesity  in  PKU  patients  resulted  from
he routine  observation  of  clinical  care  to  patients  in  SEG-
C/UFMG, conﬁrmed  by  assessments  performed  in  2007  and
009.
Cross-sectional investigations  identiﬁed  increasing
revalence rates  of  excess  weight  and  obesity,  going
rom 16.8%  and  8.8%  in  2007  to  19.8%  and  9.6%  in  2009,
espectively.
The occurrence  of  excess  weight  in  a  population  with
KU, whose  diet  is  periodically  monitored  by  nutrition-
sts, has  one  of  its  possible  justiﬁcations  in  the  restrictive
nd monotonous  character  of  the  diet,  especially  for  older
hildren and  adolescents,  who  have  autonomy  in  dietary
hoices.
Dietary transgressions  cause  variations  in  the  labora-
ory control  of  the  disease  starting  at  this  age  group  and
etabolic abnormalities  that,  in  the  medium  term,  can
ranslate into  excessive  weight  gain  and  increased  car-
iovascular risk.  Several  studies  conﬁrmed  these  control
ifﬁculties in  patients  that  acquired  dietary  autonomy.17--20
n  this  study,  the  group  of  overweight  patients  was  expected
o have  higher  concentrations  of  blood  phe  --  due  to  dietary
ransgressions --  as  reported  by  McBurnie  et  al.,3 which  could
xplain the  excess  weight  in  these  patients.  However,  it  was
eriﬁed that  most  mean  blood  phe  tests  were  elevated  in
nts  aged  4  to  15  years  that  participated  in  the  study.
Study  Groups
Normal  weight  (n  =  29)  p-value
9  (±  2.4)  0.66a
28.0  (±  10.6)  0.01b
132.1  (±  13.3)  0.67a
10  (34.5)  0.04c
19  (65.5)
21  (72.4)  0.27c
8  (28.5)
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Table  2  Blood  levels  of  total  cholesterol  and  HDL-c,  triglycerides,  blood  glucose,  and  basal  insulin  in  phenylketonuria  patients
with  excess  weight  and  normal  weight.
Variables  Study  groups
Excess  weight  (n  =  29)  Normal  weight  (n  =  29)  p-value
Cholesterol  (mg/dL)
Total 136.2  (±  22.2)  130.7  (±  20.2)  0.32a
HDL-c  34.0  (±  7.5)  37.0  (±  8.0)  0.00b
Triglycerides  (mg/dL)  109.0  (±  43.0)  74.0  (±  40.5)  0.00b
Glycemia  (mg/dL)  73.8  (±  6.4)  76.3  (±  6.3)  0.13a
Basal  insulin  (uUI/mL)  8.4  (±  8.95)  3.8  (±  5.15)  0.02b
a Student’s t-test (means ± SD).
b Mann-Whitney’s test [median (± Q3-Q1)].
Table  3  Comparison  between  the  mean  or  median  of  serum  levels  of  triglycerides,  total  cholesterol,  and  HDL-c  in  phenylke-
tonuria  patients  with  normal  weight  and  excess  weight,  according  to  pubertal  stage.
Pubertal  stage  Variable  Nutritional  status  Values
mg/dL
p
Prepubertal  (n  =  38)  Trig  Excess  weight  33.7  ±  6.4  0.00a
Normal  weight  40.1  ±  8.1
TC  Excess  weight  140.1  ±  23.5  0.24b
Normal  weight  131.1  ±  22.9
HDL-c  Excess  weight  33.7  ±  6.4  0.01b
Normal  weight  40.1  ±  8.1
Pubertal  (n  =  20)  Trig  Excess  weight  105.5  ±  57.7  0.4a
Normal  weight  83.0  ±  53.7
TC  Excess  weight  131.0  ±  36.2  0.9a
Normal  weight  132.0  ±  4.7
HDL-c  Excess  weight  36.5  ±  10.7  0.52a
Normal  weight  37.0  ±  4.0
r
w
a
w
t
H
sTrig, triglycerides; TC, total cholesterol.
a Mann Whitney Test [median (± Q3-Q1)].
b Student’s t-test (means ± SD).
both  groups  and  that  the  excess  weight  group  showed  a
higher number  of  adequate  tests  for  the  variable  fasting  phe.
Belanger-Quintan  et  al.5 and  Rocha  et  al.20 suggested  that
the excess  weight  of  PKU  patients  was  related  to  disease
severity. As  in  the  present  study  most  of  the  participants
in both  groups  had  the  severe  form  of  the  disease,  it  was
not possible  to  correlate  excess  weight  with  disease  sever-
ity. Therefore,  it  appears  that  the  excess  weight  detected  in
these patients  is  not  necessarily  related  to  food  transgres-
sion or  disease  severity.
Non-adherence  to  or  inadequacy  of  nutritional  guide-
lines for  the  treatment  of  PKU  can  cause  abnormalities
b
d
c
t
Table  4  Comparison  between  total  cholesterol/HDL-c,  blood  le
with  excess  weight  and  normal  weight.
Excess  weight  
Total  cholesterol/HDL-c  4.00  (±  0.84)  
Insulin (uUI/mL)  8.40  (±  8.95)  
HOMA 1.64  (±  1.59)  
a Mann-Whitney’s test [median (± Q3-Q1)].esulting  from  lack  or  excess  of  nutrients,21--24 and  excess
eight (and  its  consequences)  is  the  most  frequent.  Thus,
s demonstrated  by  Freedman  et  al.,25 patients  with  excess
eight evaluated  in  this  study  showed  a  positive  correla-
ion between  measures  of  WC  and  levels  of  basal  insulin  and
OMA determinations.
The low  concentrations  of  cholesterol  observed  in  this
tudy may  be  explained  by  genetic  factors,  by  cholesterol
iosynthesis inhibition,  and  also  by  an  exclusive  vegetarian
iet.10,26--29 PKU  patients  with  excess  weight,  in  addition  to
entral obesity  expressed  by  the  WC,  had  high  blood  concen-
rations of  triglycerides  and  reduced  HDL-c,  suggesting  the
vels  of  basal  insulin,  and  HOMA  in  phenylketonuria  patients
Study  groups
Normal  weight  pa
3.33  (±  0.81)  0.00
3.8  (±  5.15)  0.01
0.70  (±  1.10)  0.03
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102  
resence  of  MS.11 Low  concentrations  of  HDL-c  and  high  con-
entrations of  LDL-c,  even  isolated,  have  been  considered
s good  predictors  of  cardiovascular  risk.29,30
According  to  Burrows  et  al.,8 children  and  adolescents
ave a  three-fold  higher  risk  of  developing  MS  when  basal
nsulin and  HOMA  are  >  75th  percentile.  In  this  study,  a  higher
ercentage of  patients  with  high  levels  of  basal  insulin  and
OMA was  identiﬁed  among  those  with  excess  weight  and
t pubertal  stage  (31%  vs.  14%).  Dietary  characteristics  of
KU patients  associated  with  the  physiological  changes  of
uberty may  explain  these  ﬁndings,  which  should  constitute
arning factors  for  the  diagnosis  of  MS.  The  WHO  (World
ealth Organization)31 and  EGIR  (European  Group  for  the
tudy of  Insulin  Resistance)32 consider  insulin  resistance  to
e one  of  the  markers  of  MS.  In  patients  with  PKU  and  excess
eight, elevated  HOMA  values  were  also  found.
As  in  the  study  by  Rocha  et  al.,20 the  present  results
emonstrate that  patients  with  PKU  and  excess  weight
ehave similarly  to  obese  individuals  without  a  genetic  dis-
ase. However,  PKU  patients  with  excess  weight  may  be
ore susceptible  to  MS  due  to  factors  inherent  to  the  dis-
ase. Thus,  a  review  of  the  treatment  protocol  used  for
hese patients  is  advisable,  characterized  by  the  introduc-
ion of  simple  procedures  that  can  be  conducted  in  any
utpatient care  facility.  General  guidelines  should  empha-
ize the  need  to  maintain  the  food  free  of  phe,  control
he over-consumption  of  sugar,  as  well  as  the  importance
f incorporating  physical  activity  into  everyday  life,  as
ppropriate to  each  individual.  Clinical  control  must  include
egular measurement  of  WC  and,  when  necessary,  moni-
oring of  blood  concentrations  of  cholesterol,  triglycerides,
lucose, and  basal  insulin.
Patients  with  excess  weight  showed  higher  blood  con-
entrations of  triglycerides  and  basal  insulin,  higher  values
f total  cholesterol/HDL-C  ratio  and  HOMA  and  lower  HDL-
 levels.  The  results  of  this  study  suggest  that  patients
ith PKU  and  excess  weight  are  potentially  vulnerable  to
he development  of  MS.  It  is,  therefore,  necessary  to  con-
uct clinical  and  laboratory  monitoring  to  prevent  metabolic
hanges, as  well  as  excessive  weight  gain  and  its  con-
equences, particularly  cardiovascular  risk.  Additionally,
peciﬁc dietary  guidelines  should  be  emphasized  in  clinical
ractice, especially  for  patients  with  excess  weight,  in  order
o prevent  metabolic  inadequacies.
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